Can longer pyrotinib use keep breast cancer at bay?

NCT ID NCT05910398

Recruiting now Disease control Sponsor: RenJi Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial is testing whether extending treatment with the drug pyrotinib (either continuously or in cycles) can help prevent HER2-positive breast cancer from returning. About 488 adults who have already completed initial therapy will be randomly assigned to one of two extended dosing schedules. The main goal is to see which approach improves invasive disease-free survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pyrotinib
What this could lead to: If successful, this could show that extending pyrotinib treatment (continuously or intermittently) helps keep HER2-positive breast cancer from coming back after initial therapy.
What could go wrong: This is a Phase 3 trial, but it's still recruiting and results aren't yet known. The benefit over standard care may be small, and pyrotinib can cause side effects like diarrhea or liver issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER INVASIVE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HER2 positive breast carcinoma invasive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER INVASIVE

Contacts and locations

Locations

Renji Hospital, School of Medicine, Shanghai Jiaotong University
RECRUITING

Shanghai, 200127, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.